Geron gains as FDA approves blood disorder drug

Geron

07/06/2024 10:02

** Shares of drug developer Geron  GERN.O  surge 15.68% to
$4.50 premarket
    ** Co said late on Thursday the U.S. FDA has approved its
drug to treat transfusion-dependent anemia in patients with a
group of blood cancers called myelodysplastic syndromes (MDS)
    ** The drug will be sold under the brand name Rytelo
    ** Up to last close, stock up ~85% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))